Ratings Moves: AIR,...
Health Care: Drugs
Pharmasset Inc. (VRUS: NASDAQ)
$136.97 0.00 | 0.00%
02/24/12 - 12:18 AM ET
0.00 / 2.32M
Vol / Avg. Vol:136.97 / 136.97
Open / Prev. Close:136.97 - 136.97
Today's Range:22.64 - 137.01
52 Wk Range:6.84%
Performance YTD:TheStreet Rating:
Portfolios with VRUS
- Portfolio NameUser Type
- ContributorHigh 5s For 2011
- ContributorFive Drug Stock Winners of ...
- Contributor8 Health Care Stocks to Buy
- ContributorBreakout Stocks Of The Week...
- Contributor10 Hep C Stocks on Wall Str...
- ContributorHot Biotech Trades for Seco...
- ContributorHep C Drug Stocks in the Sp...
- UserBIG BUCKS
- UserPART 7 JPMorgan 28th Annual...
- UserBullish Tree
Latest VRUS Headlines from TheStreet
- Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale) 01.09.12 | 08:01 am
- Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion 01.07.12 | 10:01 pm
- The Next Big Thing In Biotech: 2012 Outlook
01.06.12 | 05:01 am - Inhibitex Shares Whipsawed by Cautious Analyst Comment 01.04.12 | 01:01 pm
- 5 Big Surprise Stock Winners of 2011 12.29.11 | 07:12 am
- 'Fast Money' Recap: Beaten-Up Financials Eyed 12.22.11 | 05:12 pm
- Analysts' Actions: GRPN, VRUS, MU, CVC 12.19.11 | 09:12 am
- Five Drug Stock Winners of 2011 12.19.11 | 08:12 am
- Pharmasset Inc. (VRUS): Today's Featured Drugs Loser 12.16.11 | 04:12 pm
- 10 Best Mutual Funds of 2011 You've Never Heard Of 12.16.11 | 12:12 pm
Press Releases for VRUS
- Corporate Leaders Receive Twelfth Annual Emerald Asset Management “E-3 Awards” - Business Wire 02.13.12 | 12:02 pm
- Gilead Sciences Completes Acquisition Of Pharmasset, Inc. - Business Wire 01.17.12 | 05:01 pm
- Gilead Sciences Completes Tender Offer For All Outstanding Shares Of Pharmasset, Inc. - Business Wire 01.12.12 | 01:01 am
- Pharmasset Announces Intent To Amend QUANTUM Trial - PR Newswire 12.16.11 | 08:12 am
- Bull & Lifshitz, LLP Announces Investigation Of Pharmasset, Inc. - Business Wire 11.30.11 | 10:11 pm
- The Law Firm Of Weiss & Lurie Investigates Pharmasset, Inc. - Business Wire 11.21.11 | 07:11 pm
- Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Pharmasset, Inc. - Business Wire 11.21.11 | 06:11 pm
- Pharmasset, Inc. Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate The Board Of Pharmasset, Inc. Concerning The Sale Of Pharmasset To Gilead Sciences, Inc. - PR Newswire 11.21.11 | 03:11 pm
- The Law Firm Of Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Pharmasset, Inc. In Connection With The Sale Of The Company To Gilead Sciences, Inc. - PR Newswire 11.21.11 | 02:11 pm
- Rigrodsky & Long, P.A. Announces Investigation Of Pharmasset, Inc. - Business Wire 11.21.11 | 12:11 pm
Partner Headlines for VRUS
- Biotech Stocks On A Tear: I Like Celgene - Seeking Alpha 01.13.12 | 09:01 am
- Analyzing 5 Biotech Stocks And Their Takeover Potential - Seeking Alpha 01.13.12 | 08:01 am
- The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, Inhibitex, Gilead Sciences and Pharmasset - Press Releases - Zacks 01.10.12 | 09:01 am
- Forget Dendreon, Inhibitex is the New Biotech Success Story - Benzinga 01.09.12 | 01:01 pm
- BMY Kicks Off 2012 Pharma Deals - Analyst Blog - Zacks 01.09.12 | 09:01 am
- 6 Drug Companies Favored By Hedge Funds - Seeking Alpha 01.05.12 | 09:01 am
- Pharmasset: M&A Presents Interesting Options Plays - Seeking Alpha 01.04.12 | 08:01 am
- Wedbush Securities Drops Coverage on Pharmasset on Pending Gilead Acquisition - Benzinga 12.16.11 | 04:12 pm
- JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement - Benzinga 12.16.11 | 09:12 am
- The Zacks Analyst Blog Highlights: AutoZone, Johnson & Johnson, Bristol-Myers Squibb, Gilead Sciences and Pharmasset - Press Releases - Zacks 12.07.11 | 09:12 am
